SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...
11d
SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026
SAB Biotherapeutics (NASDAQ:SABS) used a presentation at Guggenheim’s Emerging Outlook Biotech Summit 2026 to outline its ...
SAB Biotherapeutics ( (SABS)) has provided an update. On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with UBS Securities LLC to establish an at-the-market equity ...
MIAMI, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...
Zacks Investment Research on MSN
Are computer and technology stocks lagging America Movil, SAB de CV unsponsored ADR (AMX) this year?
The Computer and Technology group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amer Movil (AMX) one of those stocks right now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results